RT - Journal Article T1 - Properties and Maternal and Fetal Complications in Pre-eclampsia Patients, Case Study of Sarem Women’s Hospital JF - saremjm YR - 2019 JO - saremjm VO - 4 IS - 1 UR - http://saremjrm.com/article-1-122-en.html SP - 71 EP - 75 K1 - Preeclampsia K1 - Pregnancy complications K1 - Maternal mortality K1 - Fetal death AB - Aims: Pre-eclampsia is one of the major cause of maternal mortality and morbidity. The aim of this study was to investigate epidemiological and fetal and maternal complications in preeclamptic patients. Materials & Methods: The files of 195 patients with pre-eclampsia who were admitted to the Sarem hospital from 2010 to 2015 were investigated and information was recorded in the pre-prepared checklist. Findings: Of the total patients, 63.9% were asymptomatic, such as loss of consciousness, epigastric pain, headache and seizure. There was no case of maternal death and only one case of intrauterine fetal death (IUFD) was available in the records. Maternal complications were observed in patients. Fetal complications were observed in 26.2% of patients. Antiphospholipid syndrome was observed in 3.1% of patients with maternal complications compared to 1% of uncomplicated mothers (p=0.001). Serum glutamic-oxaloacetic transaminase (SGOT) mean was 49.5 in mothers with complications and 26.94 in mothers without complications (p=0.043). Serum glutamic-pyruvic transaminase (SGPT) mean was 60.13 in mothers with complications compared to 23.87 in uncomplicated mothers (p=0.001). Lactate dehydrogenase (LDH) mean was 2235.38 in mothers with complications and 735.02 in mothers without complications. In patients with fetal complications LDH levels were 385.35 and in cases without fetal complications 375.02. Conclusion: The level of liver enzymes and the presence of antiphospholipid syndrome are considered as predictors of maternal complications, while lactate dehydrogenase and signaling in the mother predict maternal and fetal complications. LA eng UL http://saremjrm.com/article-1-122-en.html M3 10.29252/sjrm.4.1.71 ER -